Korea/Asia, Events, IPOs, Douglas Research Advisory

Douglas Kim

Nearly 30 years of experience in the Korean/Asian equity research. Major sectors coverage include the following:
- Technology 
- Consumer 
- Special Situations/Deep Value Plays
- Tender Offers/M&As
- Holdcos/Stubs
- Asian Unicorns/Private Companies

Korea/Asia, Events, IPOs

SK Inc: Selling 1.25 Trillion Won Worth of SK Biopharm Through a PRS Contract

SK Biopharmaceuticals (326030 KS): Parent’s Stake Sale Does Not Tarnish Future Growth Prospect

Mandatory Cancellation of Treasury Shares: Final Approval by the Korean National Assembly on 24 Feb?

An Update on SK Inc (2026 High Conviction Pick)

A Mandatory Cancellation of Repurchased Treasury Shares in Korea: A Key Agenda for FSC in 2023

Treasury Burn Play: SK Inc & Big Caps in Focus as 3rd Commercial Act Nears

Douglas Research Advisory

Cross Asset Strategy

<ul>
<li>On 25 February, the Korean National Assembly FINALLY passed the third amendment to the Commercial Act requiring mandatory cancellation of treasury shares.</li>
<li>According to this new amendment, it requires that companies need to cancel newly acquired treasury shares within ONE YEAR. A SIX MONTH GRACE PERIOD applies to existing treasury shares.</li>
<li>Clearly South Korea equity market's strong outperformance in the past one year suggests a case for INTERNATIONAL DIVERSIFICATION.  </li>
</ul>


On 25 February, the Korean National Assembly FINALLY passed the third amendment to the Commercial Act requiring mandatory cancellation of treasury shares.
According to this new amendment, it requires that companies need to cancel newly acquired treasury shares within ONE YEAR. A SIX MONTH GRACE PERIOD applies to existing treasury shares.
Clearly South Korea equity market's strong outperformance in the past one year suggests a case for INTERNATIONAL DIVERSIFICATION.  


한국 국회, 마침내 자기주식 의무소각 법안 통과